Livergenix is a metabolic drug discovery company. We turn patient origin data into a continuous engine for new therapeutic programs, anchored in the biology of real human disease.
The economics of new medicines are constrained by high upfront capital, long timelines, and poor early stage translation. Pharma is responding by externalising early discovery. Meanwhile, metabolic and liver disease keep climbing. We built Livergenix to close that gap.
Livergenix is built as a launch system that repeatedly produces and advances therapeutic programs in metabolic disease. The key input is direct access to human origin data, which anchors discovery in biology that translates clinically.
Our current portfolio is intentionally focused. Every asset is sourced from validated patient origin biology and pursued only where the human evidence is decisive.
Stages: Discovery, Validation & Optimization, Lead Development, IND Enabling, Clinical
A small, senior team. Operators, clinicians and computational scientists who built the field they now work in.
Scientists, clinicians, partners, investors. We want to talk to anyone who shares the urgency.
hello@livergenix.io →